Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus bortezomib + lenalidomide + dexamethasone vs bortezomib + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
2024-514417-34-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoint: Progression free survival (PFS). Planned start Sep 2024; status: authorised.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514417-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514417-34-00.